Streetbeat News

Partnerships

PLSE

Pulse Biosciences, Inc. (NASDAQ:PLSE) announces leadership changes to support growth, appointing Burke T. Barrett as CEO and Kevin Danahy as Chief Commercial Officer. These changes come as the company prepares for the pilot launch of its FDA-cleared CellFX nsPFA Percutaneous Electrode System.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:31 pm

BLNK

Blink Charging has been selected as one of the official EV charging partners for the State of New York, marking a significant milestone for the company in expanding its footprint in the EV infrastructure sector.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:29 pm

AKLI

Akili is exploring potential strategic alternatives to enhance shareholder value, which may include partnerships, a sale, or other options. This decision reflects the company's commitment to maximizing its assets and strategic position.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:24 pm

KRMD

KORU Medical Systems, Inc. (KRMD) has signed a Phase III clinical supply agreement for a novel enzyme replacement therapy aimed at treating a rare endocrinological disease. This marks a significant milestone in the collaboration announced in July 2023, with the KORU Medical Freedom System passing validation testing for subcutaneous infusion administration of the drug. The Phase III trial will evaluate bi-weekly infusions using the Freedom System. The drug has received Breakthrough Therapy, Rare Pediatric Disease, and Fast Track designations by the FDA, along with Orphan Drug designation in the US and Europe.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:22 pm

ZPTA

Zapata AI has announced a partnership with Tech Mahindra to use industrial generative AI for transforming network and customer operations for global telecom customers. This collaboration aims to leverage AI technologies to enhance operational efficiencies and customer experiences in the telecom sector.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:04 pm

QBTS

D-Wave Quantum Inc (QBTS) receives positive analyst coverage with a focus on its fast anneal technology, which accelerates quantum processing speeds. Needham, Benchmark, and Piper Sandler analysts reiterate Buy or Overweight ratings with price targets ranging from $2.50 to $4. Despite reporting lower-than-expected revenues for the quarter at $2.5 million, the company shows strong year-over-year bookings growth and technological advancements, including the development of a 4,800+ qubit processor for its upcoming Advantage2 system.

Portfolio Pulse from Anusuya Lahiri

May 14, 2024 | 6:54 pm

AMC

GME

IWM

PLUG

SPWR

UUP

Wall Street trades flat amid mixed producer inflation data and anticipation for consumer inflation report. Fed Chair Powell sees prolonged current monetary policy, while President Biden imposes significant tariffs on Chinese imports. The U.S. dollar index and Treasury yields fell, while small caps and meme stocks like GameStop and AMC surged. Commodities saw mixed movements, and Bitcoin dropped. Key ETFs and stocks like Insulet, Plug Power, SunPower, and Delcath Systems reacted to various news, including earnings and significant financial developments.

Portfolio Pulse from Piero Cingari

May 14, 2024 | 5:59 pm

EQNR

ICOW

PWER

Equinor ASA (NYSE:EQNR) has entered into an asset swap agreement with Petoro, aiming to streamline operations in Norway's Haltenbanken region. This deal will adjust Equinor's ownership in several fields, enhancing its position in Heidrun and Noatun while reducing stakes in Tyrihans, Castberg, Carmen, and Beta. The swap, effective from January 1, 2025, is pending regulatory and Norwegian Parliament approvals. Equinor's strategy focuses on developing the Norwegian continental shelf with high production and lower emissions by 2035. The swap is expected to simplify commercial agreements, lower operating costs, and facilitate new developments.

Portfolio Pulse from Lekha Gupta

May 14, 2024 | 5:53 pm

ABBV

AMRS

CRBP

CRDL

HRMY

JAZZ

NTEC

PFE

Roy Bingham, CEO of BDSA, projects the U.S. cannabis market to reach nearly $46 billion by 2028, driven by adult-use and medical market expansion. The DEA's reclassification of cannabis to Schedule III is expected to spur medical research and investment, with significant growth anticipated in pharmaceutical applications and medical cannabis products. This rescheduling may reduce financial pressures on cannabis businesses and attract investment from healthcare and pharmaceutical companies. Despite federal restrictions, the shift is seen as an opportunity for healthcare and pharmaceutical industries to invest in cannabinoid research, potentially impacting medication use and fostering innovation in the sector.

Portfolio Pulse from Nicolás Jose Rodriguez

May 14, 2024 | 5:32 pm

SAGE

Sage Therapeutics' CEO announced the company is open to partnerships for its Huntington's disease drug, citing significant inbound interest. This openness to collaboration could potentially accelerate the drug's development and market entry, signaling a strategic move to enhance its pipeline and market presence.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 5:31 pm